Table 6.
Laboratory measurements at 6, 12, 24, and 36 months after kidney donation.
| Test | Group | Visit (Time after donation) | P-Valuesa | |||||
|---|---|---|---|---|---|---|---|---|
| 6 Mo | 12 Mo | 24 Mo | 36 Mo | Donors vs Controlsb |
Visitc | Interactiond | ||
| Hemoglobin (g/dL) | Controls | 13.6±1.4 (195) |
13.4±1.4 (191) |
13.6±1.2 (175) |
13.6±1.2 (173) |
0.003 | <0.001 | 0.02 |
| Donors | 13.2±1.2 (200) |
13.1 ±1.3 (197) |
13.4±1.3 (183) |
13.5±1.4 (172) |
||||
| Leukocyte count (/µL) | Controls | 6.0±1.7 (195) | 6.1 ±1.8 (190) | 6.0±1.6 (174) | 6.0±1.8 (157) | 0.1 | 0.6 | 0.8 |
| Donors | 5.8±1.5 (200) |
5.9±1.8 (196) |
5.7±1.5 (182) |
5.8±1.6 (169) | ||||
| Serum albumin (mg/dL) | Controls | 4.07±0.33 (198) |
4.03±0.30 (193) |
4.06±0.32 (182) |
4.02±0.27 (173) |
0.9 | 0.008 | 0.9 |
| Donors | 4.06±0.31 (200) |
4.03±0.30 (198) |
4.05±0.30 (185) |
4.00±0.27 (182) |
||||
| CRP (mg/dL) | Controls | 1.4 [0.6–3.1] (198) |
1.2 [0.5–2.8] (193) |
1.2 [0.5–2.6] (182) |
1.0 [0.6–2.4] (173) |
0.7e | 0.6e | 0.01e |
| Donors | 1.2 [0.7–2.9] (200) |
1.3 [0.6–2.5] (196) |
1.1 [0.6–2.5] (185) |
1.2 [0.6–3.0] (182) |
||||
| Fibrinogen (mg/dL) | Controls | 305±67 (198) |
306±74 (193) |
311±65 (182) |
306±67 (173) |
0.8 | 0.2 | 0.3 |
| Donors | 300±72 (198) |
310±66 (196) |
309±81 (185) |
309±70 (181) |
||||
| Homocysteine (mg/L) | Controls | 1.21 ±0.34 (196) |
1.21 ±0.37 (193) |
1.28±0.43 (182) |
1.23±0.38 (173) |
<0.001 | 0.6 | 0.05 |
| Donors | 1.49±0.43 (198) |
1.46±0.42 (196) |
1.50±0.42 (185) |
1.41 ±0.43 (182) |
||||
| Uric acid (mg/dL) | Controls | 4.9±1.2 (198) |
4.9±1.2 (193) |
4.9±1.2 (182) |
5.0±1.1 (173) |
<0.001 | <0.001 | 0.2 |
| Donors | 5.3±1.1 (200) |
5.2±1.2 (196) |
5.4±1.2 (185) |
5.5±1.3 (182) |
||||
| Serum potassium (mmol/L) | Controls | 4.14±0.32 (197) |
4.10±0.29 (187) |
4.12±0.31 (177) |
4.11 ±0.28 (172) |
0.006 | 0.1 | 0.9 |
| Donors | 4.20±0.29 (199) |
4.19±0.35 (193) |
4.20±0.32 (181) |
4.17±0.27 (178) |
||||
| Serum calcium (mg/dL) | Controls | 9.19±0.38 (198) |
9.18±0.42 (193) |
9.17±0.41 (182) |
9.21 ±0.40 (173) |
0.4 | 0.2 | 0.7 |
| Donors | 9.24±0.42 (200) |
9.18±0.41 (196) |
9.24±0.38 (185) |
9.26±0.40 (182) |
||||
| Serum phosphorus (mg/dL) | Controls | 3.49±0.48 (198) |
3.55±0.46 (190) |
3.52±0.46 (178) |
3.51 ±0.46 (172) |
<0.001 | 0.007 | 0.003 |
| Donors | 3.30±0.48 (200) |
3.37±0.51 (195) |
3.43±0.51 (182) |
3.42±0.51 (178) |
||||
| PTH (pg/mL) | Controls | 42.8±15.6 (198) |
42.4±16.7 (193) |
43.6±16.3 (182) |
43.2±17.5 (173) |
<0.001 | 0.7 | 0.3 |
| Donors | 52.7±20.9 (200) |
52.9±22.1 (196) |
51.7±20.6 (185) |
52.5±24.1 (182) |
||||
| Cholesterol (mg/dL) | Controls | 186±36 (197) |
185±37 (193) |
188±34 (182) |
190±35 (173) |
0.9 | 0.01 | 0.8 |
| Donors | 186±35 (199) |
184±32 (195) |
186±36 (185) |
188±35 (182) |
||||
| LDL cholesterol (mg/dL) | Controls | 111±30 (193) |
111±30 (190) |
113±29 (182) |
115±30 (172) |
0.7 | 0.03 | 0.1 |
| Donors | 110±31 (193) |
108±30 (194) |
109±30 (184) |
111±31 (180) |
||||
| HDL cholesterol (mg/dL) | Controls | 54.9±16.4 (195) |
54.5±15.9 (193) |
56.8±16.2 (182) |
56.2±16.0 (172) |
0.9 | <0.001 | 0.2 |
| Donors | 54.1 ±13.9 (197) |
55.1 ±14.2 (195) |
56.6±15.8 (185) |
56.5±15.0 (181) |
||||
| Triglycerides (mg/dL) | Controls | 80 [59–119] (197) |
77 [62–117] (193) |
78 [59–104] (182) |
76 [59–107] (173) |
0.1e | 0.1e | 0.6e |
| Donors | 84 [64–124] (199) |
81 [61–122] (195) |
84 [65–127] (185) |
89 [61–124] (182) |
||||
| Lipoprotein(a) (mg/dL) | Controls | 16.0 [5.0– 43.0] (198) |
15.0 [5.0–44.0] (193) | 15.0 [5.0– 42.0] (182) |
15.0 [5.0– 45.0] (173) |
0.3e | 0.9e | 0.4e |
| Donors | 20.0 [5.0– 54.5] (200) |
18.0 [5.0–51.5] (196) | 20.0 [11.0– 49.0] (185) |
18.5 [10.0– 45.0] (182) |
||||
| Hemoglobin A1c (%) | Controls | 5.3±0.35 (195) |
5.3±0.34 (190) | 5.4±0.34 (181) |
5.4±0.33 (173) |
0.1 | <0.001 | 0.5 |
| Donors | 5.3±0.31 (197) |
5.3±0.38 (191) | 5.3±0.32 (181) |
5.3±0.33 (181) |
||||
| Glucose (mg/dL) | Controls | 91.2±8.94 (197) |
91.1 ±8.66 (193) | 92.5±9.23 (182) |
93.2±9.03 (173) |
0.04 | <0.001 | 0.7 |
| Donors | 89.2±8.51 (199) |
90.7±11.4 (195) | 90.6±8.72 (185) |
91.4±8.78 (182) |
||||
| Insulin (pmol/L) | Controls | 39 [26–64] (192) |
36 [24–54] (188) | 39 [25–65] (174) |
42[29–64] (166) |
0.9e | <0.001e | 0.2e |
| Donors | 36 [24–54] (198) |
41 [24–66] (194) | 43[30–63] (183) |
43[31–66] (171) |
||||
| HOMA-IR | Controls | 1.5 [0.96–2.5] (191) |
1.4 [0.88–2.2] (188) |
1.5 [0.94–2.5] (174) |
1.6 [1.1–2.6] (166) |
0.7e | <0.001e | 0.2e |
| Donors | 1.4 [0.91– 2.1](197) |
1.4 [0.95– 2.5](193) |
1.7 [1.0–2.3] (183) |
1.6 [1.1–2.7] (171) |
||||
Note: Values are given as mean ± standard deviation or median [interquartile range] (number sampled). Conversion factors for units: fibrinogen in mg/dL to µmol/L, × 0.0294; homocysteine in mg/L to × µmol/L, × 7.397; uric acid in mg/dL to µmol/L, × 59.48; calcium in mg/dL to mmol/L, × 0.2495; phosphorus in mg/dL to mmol/L, × 0.3229; cholesterol in mg/dL to mmol/L, × 0.02586; triglycerides in mg/dL to mmol/L, × 0.01129; glucose in mg/dL to mmol/L, × 0.05551.
Abbreviations and definitions: CRP, C-reactive protein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance, where log(HOMA IR) =log[(insulin × glucose)/22.5], with insulin in µU/mL and glucose in mmol/L; LDL, low-density lipoprotein; mGFR, measured glomerular filtration rate (by iohexol plasma clearance); PTH, parathyroid hormone.
Analysis of variance with repeated measures. Each variable was analyzed separately and no adjustment was made for multiple comparisons. Values not normally distributed were logarithmically transformed before analysis.
Donors versus controls P values test overall differences between donors and controls.
Visit P values test differences between the 4 visits.
Interaction P values test the interaction between donors versus controls and between visits.
Based on logarithmically transformed values